Ramucirumab Plus Docetaxel Improves Outcomes in Bladder CancerRamucirumab Plus Docetaxel Improves Outcomes in Bladder Cancer
Adding ramucirumab to docetaxel showed promising results as a second-line therapy in metastatic urothelial carcinoma. Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
More News: Bladder Cancer | Cancer | Cancer & Oncology | Carcinoma | Docetaxel | Health | Hematology | Taxotere